Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects of Arzoxifene on Vertebral Fracture Incidence and on Invasive Breast Cancer Incidence in Postmenopausal Women With Osteoporosis or With Low Bone Density.

NCT00088010 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00088010
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00088010 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effects of Arzoxifene on Vertebral Fracture Incidence and on Invasive Breast Cancer Incidence in Postmenopausal Women With Osteoporosis or With Low Bone Density.
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2004
Completion date
November 30, 2009
Enrollment
9,369 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

osteoporosis, postmenopausal